A range with both ends published
The page asks how much it costs and answers with a floor and a ceiling, saying the figure varies with medication dosage and goals. The ceiling is more than three times the floor.
Publishing both ends is better than the starting-at figure most of this comparison offers, because it tells a reader what the top of the ladder looks like rather than only the bottom. It is still a range: it answers what a month might cost, not what a month will cost.
This row records the bottom of the range with both endpoints and the dose clause in its qualifier, the same treatment another brand row on this roster already carries. Nothing here converts a range into a price by choosing a point inside it.
One figure, two molecules
The page states that a qualifying patient will be prescribed a compounded semaglutide or tirzepatide medication, and the range covers whichever one they get. Nothing on the page says what either costs on its own.
Six of the seventy-three sellers here publish a figure that names no molecule while still buying the medication. This roster records those with an unscoped compound rather than guessing which drug a figure belongs to, because a price attached to the wrong molecule is worse than a price attached to none.
The two drugs are not interchangeable and they are not priced alike anywhere else in this comparison. A reader who has decided which one they want cannot find out here what it costs.
Two named charges with no numbers
The same paragraph that gives the range says that nurse practitioner calls and IV drips can be added for an additional fee. Both are named; neither is priced.
That is a real gap on a page whose whole purpose is to answer a cost question, and it is compounded by a sitewide line saying services, therapies and prices may vary per location. The published range is a national description of a locally set price.
Fifty-three of the seventy-three sellers here name no compounding pharmacy, and this row is one of them. What is prescribed is stated plainly as a compounded preparation; who prepares it is not.
The membership is for something else entirely
This chain runs a membership, and it is easy to assume it applies to the medication. It does not. The membership buys credits for the chain's core therapies and IV drips, and the GLP-1 page mentions it only as an optional way to get more value out of those therapies and nurse practitioner calls.
So this row does not record a membership fee on top of the medication price, because that would add a charge no GLP-1 buyer has to pay. It records instead that no membership figure is published at all, which is also true: the seller says prices vary by studio and by membership type and directs a reader to a local studio page. The three named tiers are described entirely in credits, with no dollar figure anywhere.
One priced membership fact does exist and it is location-scoped: an up-charge is added to one membership's IV appointments in one state's studios. It has nothing to do with the medication, and it is recorded where it belongs rather than beside a drug price.
Named clinicians, a studio count, no state list
Forty of the seventy-three sellers here name an individual prescribing clinician, and this is one: a chief medical officer and a chief science officer, both named with credentials. The company also states that medical services are provided by an independently owned physician practice, which is a structural disclosure rather than a marketing one.
Forty-one of the seventy-three sellers here publish no service area, and this row is one of them. What is published is a studio count, and the locations page is a search tool that renders no list of states at all.
The company names its operating entity and its trading name and publishes a governing-law state, which is fuller corporate disclosure than a good deal of this comparison offers.
The GLP-1 page cites two named clinical trials with percentage figures. Those are trial results, attributed to the trials, and the page prints its own caveat beside them: real-world results from these therapies often differ. That caveat is the seller's and it is worth repeating.
Restore Hyper Wellness's published pricing
| Medication | Price | Verified |
|---|---|---|
| Glp-1 (compounded) | $225/moThe bottom of a published range, quoted verbatim: "How much does it cost? Only pay for what you need! Costs vary and range from $225 - $750/month based on your medication dosage and goals." ⚠ The range is dose-driven and the top is more than three times the bottom. Two further charges are named and not priced on the same page: "Access to science-backed therapies such as IV Drips and ongoing Nurse Practitioner calls can be added for an additional fee." Sitewide: "Services, therapies, nutrients and prices may vary per location." | September 2026source |
compareglp may earn a commission when a reader signs up with a provider through a link on this site. 4 of the 73 providers reviewed here are paid partners today; the other 69 are not. See how this works.
See Restore Hyper Wellness's current price →Good fit if
- Readers who want an in-studio option, with the medication either shipped home or collected in person with staff available to help.
- Buyers who can act on a range and want both ends of it published rather than a starting figure alone.
- People who want the prescribing clinicians named as individuals with credentials.
- Anyone who values a seller printing its own caveat beside the trial results it cites.
Look elsewhere if
- Anyone who needs to know what a specific month costs. The top of the published range is more than three times the bottom.
- Readers who have chosen a molecule. One figure covers both compounds and neither is priced on its own.
- Buyers who want an FDA-approved product. Everything here is compounded.
- People who need a fixed national price. The studios are individually owned and the site says prices may vary per location.
- Anyone who needs the compounding pharmacy named, or a list of states.
How this review was verified
- Read the GLP-1 page and the memberships page in a browser and audited every dollar element for computed opacity, visibility and a real laid-out rectangle before recording a figure.
- Recorded the bottom of the published range with both endpoints and the seller's own dose clause inside the qualifier, rather than choosing a point inside a range and calling it a price.
- Recorded the compound as unscoped, because one figure covers a compounded semaglutide or a compounded tirzepatide and the page does not separate them.
- Recorded the membership as publishing no figure, and did not attach it to this row as a required fee. It buys therapy credits rather than medication, and the GLP-1 page treats it as optional added value; marking it required would have added a charge to this row that no buyer of the medication has to pay.
- Recorded the two named but unpriced add-ons — nurse practitioner calls and IV drips — in the price qualifier where a reader will see them beside the figure.
- Recorded the studio count as a count and not as a service area; the locations page is a search tool and renders no list of states.
- Took the operating entity, the trading name and the governing-law state from the terms verbatim.
- Attributed the trial percentages on the page to the trials and kept the seller's own caveat about real-world results beside them.
- Searched the agency's published warning-letter record for the trading name and the operating entity, 2017 to 2026, with controls in the same pass, and read every returned row: none names this company. That search covers warning letters only; untitled letters are published separately and were not searched.
- Took the priced page's URL from the site's own links after a plausible guessed path returned a not-found response, and probed the host with a nonsense path at two depths in the same run as the reading.